Search results for "Rejection"

showing 10 items of 169 documents

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

SARS-CoV-2-specific Cell-mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19.

2021

BACKGROUND: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown. METHODS: We enumerated SARS-CoV-2-specific interferon-I³-producing CD69+ CD4+ and CD8+ T cells at months 4 and 6 from the diagnosis of coronavirus disease 2019 (COVID-19) in 21 KT recipients by intracellular cytokine staining. Overlapping peptides encompassing the SARS-CoV-2 spike (S) glycoprotein N-terminal 1- to 643-amino acid sequence and the membrane protein were used as stimulus. SARS-CoV-2 IgG antibodies targeting the S1 protein were assessed by ELISA at month 6. RESULTS: Detectable (≥0.1…

AdultCD4-Positive T-LymphocytesGraft RejectionMalemedicine.medical_specialty030230 surgeryCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesImmunocompromised HostInterferon-gamma0302 clinical medicineCOVID-19 TestingImmunityInternal medicinemedicineHumansInterferon gammaskin and connective tissue diseasesKidney transplantationAgedTransplantationImmunity Cellularbiologybusiness.industrySARS-CoV-2CD69COVID-19Middle Agedmedicine.diseaseKidney TransplantationTacrolimusTransplant RecipientsCOVID-19 Drug TreatmentMonoclonalbiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessCD8Immunosuppressive Agentsmedicine.drugFollow-Up StudiesTransplantation
researchProduct

Antibodies to vascular endothelial cells in chronic rejection of renal allografts.

2000

AdultCytotoxicity ImmunologicGraft RejectionMalePathologymedicine.medical_specialtyTime FactorsAdolescentT-LymphocytesIsoantibodiesMedicineHumansTransplantation HomologousBlood TransfusionCells CulturedImmunosuppression TherapyTransplantationKidneyB-Lymphocytesbiologybusiness.industryHistocompatibility Antigens Class IMiddle AgedKidney TransplantationTransplantationEndothelial stem cellmedicine.anatomical_structureImmunologyHumoral immunityAntibody Formationbiology.proteinSurgeryFemaleEndothelium VascularAntibodybusinessBlood vesselFollow-Up StudiesTransplantation proceedings
researchProduct

16thIHIW: Anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates

2012

Summary In this multicentre study, sera from 803 retransplant candidates, including 775 kidney transplant recipients, were analysed with regard to the presence and specificity of anti-HLA alloantibodies of the IgA isotype using a modified microsphere-based platform. Of the kidney recipients, nearly one-third (n = 237, 31%) had IgA alloantibodies. Mostly, these antibodies were found in sera that also harboured IgG alloantibodies that could be found in a total of 572 (74%) of patients. Interestingly, IgA anti-HLA antibodies were preferentially targeting HLA class I antigens in contrast to those of the IgG isotype, which targeted mostly both HLA class I and II antigens. Donor specificity of th…

AdultGraft RejectionAdolescentImmunologyMedizinHuman leukocyte antigenMicrosphereAntigenAntibody SpecificityHLA AntigensIsoantibodiesGeneticsHumansMedicineIgg isotypeTypingChildMolecular BiologyGenetics (clinical)AgedAged 80 and overbiologybusiness.industryHistocompatibility TestingHistocompatibility Antigens Class IClass I AntigensInfantGeneral MedicineMiddle AgedKidney TransplantationVirologyIsotypeTissue DonorsAntibodies Anti-IdiotypicImmunoglobulin AChild PreschoolImmunoglobulin GImmunologybiology.proteinFemaleAntibodybusinessInternational Journal of Immunogenetics
researchProduct

Chemokines: reliable markers for diagnosis of rejection and inflammation following orthotopic liver transplantation.

2001

AdultGraft RejectionChemokinePathologymedicine.medical_specialtyOrthotopic liver transplantationAdolescentInflammationDiagnosis DifferentialPostoperative ComplicationsmedicineHumansReliability (statistics)AgedInflammationTransplantationbiologybusiness.industryMiddle AgedLiver TransplantationTransplantationChemokines CCCytomegalovirus Infectionsbiology.proteinSurgerymedicine.symptombusinessTransplantation proceedings
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct

Detection of Anti-MICA Antibodies in Patients Awaiting Kidney Transplantation, during the Post-transplant Course, and in Eluates from Rejected Kidney…

2005

Previously we have reported on the development of antibodies against MICA alleles in kidney transplant recipients. These alloantibodies have now been determined using a new assay using Luminex beads bound to soluble recombinant MICA antigens produced in insect cells. In the present study we have analyzed sera from 85 kidney transplant recipients on the waiting list and 66 patients transplanted within the last 4 years and 59 acid eluates obtained from allograft nephrectomy specimens. Many of the patients in those groups were sensitized and some had previous transplants (waiting list: 15%; post-tx: 7.6%; eluates 22%) and their sera were found to contain anti-human leukocyte antigen (HLA) and …

AdultGraft RejectionMaleImmunologyHuman leukocyte antigenPathogenesisAntigenIsoantibodiesmedicineHumansImmunology and AllergyKidney transplantationKidneybiologyHistocompatibility Antigens Class IGeneral MedicineFlow Cytometrymedicine.diseaseKidney TransplantationRecombinant ProteinsTransplant rejectionstomatognathic diseasesmedicine.anatomical_structureImmunizationLuminescent MeasurementsImmunologybiology.proteinFemaleAntibodyHuman Immunology
researchProduct

Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation

2000

Clinical trials using quadruple immunosuppression that include the combination of tacrolimus and mycophenolate mofetil have been shown to reduce the incidence of acute rejection episodes in simultaneous pancreas-kidney (SPK) transplantation. In an attempt to obtain a low rejection rate without antibody induction therapy, we undertook a prospective study of combined tacrolimus and mycophenolate mofetil and steroids as primary immunosuppression for SPK transplantation. In this study, we analyzed 17 patients who received low-dose intravenous tacrolimus as induction therapy. This was combined with oral tacrolimus, mycophenolate mofetil, and steroids as the primary immunosuppression regimen. The…

AdultGraft RejectionMaleNephrologymedicine.medical_specialtyBiopsymedicine.medical_treatmentUrinary Bladderchemical and pharmacologic phenomenaPancreas transplantationGastroenterologyTacrolimusMycophenolic acidInternal medicinemedicineHumansKidney transplantationTransplantationLeukopeniabusiness.industryImmunosuppressionMiddle AgedMycophenolic Acidmedicine.diseaseKidney TransplantationTacrolimusTransplantationsurgical procedures operativeDrug Therapy CombinationFemaleSteroidsPancreas Transplantationmedicine.symptombusinessmedicine.drugTransplant International
researchProduct

The role of monocyte chemoattractant protein-1 in orthotopic liver transplantation.

2003

Hepatic ischemia reperfusion injury as well as acute graft rejection (RE) after orthotopic liver transplantation (OLT) are associated with leukocyte invasion of the graft. Local synthesis of chemokines is a key reaction in the recruitment and activation of inflammatory leukocytes and consequent liver damage. In this paper we describe the role of monocyte chemoattractant protein (MCP)-1 (CCL2) in human OLT. We investigated the serum CC-chemokine levels for MCP-1 by specific ELISAs after OLT in 105 human liver allografts between September 1997 and January 2001. One hour after reperfusion we saw a significant (t test) increase of MCP-1 in peripheral blood (92.5 +/- 85.8 pg/mL to 774.2 +/- 319.…

AdultGraft RejectionMalePathologymedicine.medical_specialtyChemokineOrthotopic liver transplantationAdolescentCCL2GastroenterologyInternal medicinemedicineHumansChemokine CCL2AgedRetrospective StudiesTransplantationbiologyHuman liverbusiness.industryMiddle Agedmedicine.diseasePeripheral bloodHepatic ischemiaLiver Transplantationsurgical procedures operativeAcute DiseaseReperfusionbiology.proteinRegression AnalysisSurgeryFemalebusinessReperfusion injuryBiomarkersMonocyte chemoattractant proteinTransplantation proceedings
researchProduct